Filtered By:
Therapy: Statin Therapy
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 179 results found since Jan 2013.
Novel function of fluvastatin in attenuating oxidized low-density lipoprotein-induced endothelial cell ferroptosis in a glutathione peroxidase4- and cystine-glutamate antiporter-dependent manner
Exp Ther Med. 2021 Nov;22(5):1275. doi: 10.3892/etm.2021.10710. Epub 2021 Sep 8.ABSTRACTOxidized low-density lipoprotein (ox-LDL) induces endothelial cell apoptosis and dysfunction. Statins are drugs that are clinically used to lower serum cholesterol levels, and they have been shown to exert vascular protective effects. In the present study, human umbilical vein endothelial cells were transfected with scramble control siRNA or siRNA specific for glutathione peroxidase (GPx)4 or cystine-glutamate antiporter (xCT). MTT, Matrigel and Transwell assays were used to evaluate cell proliferation, tube formation and migration, res...
Source: Experimental and Therapeutic Medicine - October 1, 2021 Category: General Medicine Authors: Qing Li Chang Liu Liang Deng Enrui Xie Nishant Yadav Yuanyuan Tie Zheng Cheng Jie Deng Source Type: research
Inclisiran in lipid management: A Literature overview and future perspectives
Biomed Pharmacother. 2021 Sep 23;143:112227. doi: 10.1016/j.biopha.2021.112227. Online ahead of print.ABSTRACTPrimary and secondary prevention protocols aim at reducing the plasma levels of lipids - with particular reference to low-density lipoprotein cholesterol (LDL-C) plasma concentrations - in order to improve the overall survival and reduce the occurrence of major adverse cardiovascular events. The use of statins has been widely considered as the first-line approach in lipids management as they can dramatically impact on the cardiovascular risk profile of individuals. The introduction of ezetimibe and proprotein conve...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 26, 2021 Category: Drugs & Pharmacology Authors: Pietro Scicchitano Michele Milo Rosanna Mallamaci Micaela De Palo Pasquale Caldarola Francesco Massari Domenico Gabrielli Furio Colivicchi Marco Matteo Ciccone Source Type: research
Inclisiran in dyslipidemia
Drugs Today (Barc). 2021 May;57(5):311-319. doi: 10.1358/dot.2021.57.5.3277083.ABSTRACTCardiovascular disease (CVD) is the leading cause of death worldwide. Hypercholesterolemia has been shown to be one of the most important risk factors for CVD. Statins are currently the standard of care for the management of hypercholesterolemia. However, certain patients on statin therapy fail to achieve the desired low-density lipoprotein cholesterol (LDL-C) goals or are intolerant to statins due to side effects (mostly myalgias). The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the subsequent development of P...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: C E Kosmas A Mu ñoz Estrella A Sourlas D Pantou Source Type: research
